DK3110840T3 - A22k, desb27, b29r, des b30, ved epsilon-position af lysin 22 acyleret human insulinanalog - Google Patents

A22k, desb27, b29r, des b30, ved epsilon-position af lysin 22 acyleret human insulinanalog Download PDF

Info

Publication number: DK3110840T3
Authority: DK; Denmark
Prior art keywords: desb27; lysin; des; human insulin; insulin analog
Prior art date: 2014-02-28

Application number

DK15707102.8T

Other languages

English (en)

Inventor

Susanne Hostrup

Martin Münzel

Claudia Ulrich Hjørringgaard

Christian Fledelius

Peter Madsen

Thomas Børglum Kjeldsen

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-02-28

Filing date

2015-02-26

Publication date

2020-11-02

2015-02-26 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2020-11-02 Application granted granted Critical

2020-11-02 Publication of DK3110840T3 publication Critical patent/DK3110840T3/da

Links

101150019032 B29R gene Proteins 0.000 title 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 title 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Toxicology (AREA)
Hematology (AREA)
Obesity (AREA)
Immunology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Oil, Petroleum & Natural Gas (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)

DK15707102.8T 2014-02-28 2015-02-26 A22k, desb27, b29r, des b30, ved epsilon-position af lysin 22 acyleret human insulinanalog DK3110840T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP14157215		2014-02-28
PCT/EP2015/053989 WO2015128403A2 (en)	2014-02-28	2015-02-26	Novel insulin derivatives and the medical uses hereof

Publications (1)

Publication Number	Publication Date
DK3110840T3 true DK3110840T3 (da)	2020-11-02

Family

ID=50184804

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK15707102.8T DK3110840T3 (da)	2014-02-28	2015-02-26	A22k, desb27, b29r, des b30, ved epsilon-position af lysin 22 acyleret human insulinanalog

Country Status (23)

Country	Link
US (1)	US10040839B2 (da)
EP (1)	EP3110840B1 (da)
JP (1)	JP6580583B2 (da)
KR (1)	KR20160125988A (da)
CN (1)	CN106459171B (da)
AR (1)	AR099569A1 (da)
AU (1)	AU2015222135B2 (da)
BR (1)	BR112016017193A2 (da)
CA (1)	CA2941103A1 (da)
DK (1)	DK3110840T3 (da)
ES (1)	ES2831848T3 (da)
HR (1)	HRP20201732T1 (da)
HU (1)	HUE051355T2 (da)
IL (1)	IL246757B (da)
MX (1)	MX368387B (da)
PL (1)	PL3110840T3 (da)
PT (1)	PT3110840T (da)
RS (1)	RS61137B1 (da)
RU (1)	RU2684456C2 (da)
SA (1)	SA516371705B1 (da)
SI (1)	SI3110840T1 (da)
TW (1)	TWI686403B (da)
WO (1)	WO2015128403A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20170028031A1 (en) *	2014-03-07	2017-02-02	Klavs Holger Jørgensen	Novel fast acting insulin preparations
ES2908373T3 (es)	2015-08-25	2022-04-28	Novo Nordisk As	Nuevos derivados de insulina y los usos médicos de los mismos
CA3294636A1 (en) *	2016-11-21	2026-02-10	Case Western Reserve University	Rapid-acting insulin analogues of enhanced stability
KR101909052B1 (ko) *	2017-02-09	2018-10-17	강원대학교산학협력단	인슐린의 a 사슬로부터 유래된 펩타이드 단편 및 이를 포함하는 당뇨병 또는 당뇨병성 창상의 예방 또는 치료용 약학 조성물
JP2020513019A (ja) *	2017-04-05	2020-04-30	ノヴォノルディスクアー／エス	オリゴマー伸長インスリン−Ｆｃコンジュゲート
JOP20190273A1 (ar) *	2017-05-26	2019-11-24	Lilly Co Eli	مركب إنسولين معالج بأسيل
US10919949B2 (en) *	2017-08-17	2021-02-16	Novo Nordisk A/S	Acylated insulin analogues and uses thereof
WO2019079710A1 (en)	2017-10-19	2019-04-25	Buice Mona E	TOPIC COMPOSITION FOR ENHANCED WOUND WOUND HEALING
RU2020128624A (ru)	2018-02-27	2022-03-28	Зп Спв 3 К/С	Аналоги компстатина и их медицинское применение
TWI829687B (zh) *	2018-05-07	2024-01-21	丹麥商諾佛儂迪克股份有限公司	包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
KR20210102347A (ko)	2018-12-11	2021-08-19	사노피	인슐린 수용체 결합 친화성이 감소된 인슐린 유사체
JP7432531B2 (ja)	2019-02-13	2024-02-16	住友ファーマ株式会社	システイン残基を有するヘミアスタリン誘導体
WO2020166592A1 (ja) *	2019-02-13	2020-08-20	大日本住友製薬株式会社	ヘミアスタリン誘導体とその抗体薬物複合体
BR112022003760A2 (pt) *	2019-08-27	2022-05-31	Zp Spv 3 K/S	Análogos de compstatina e seus usos médicos
DK4073097T3 (da)	2019-12-11	2024-08-19	Novo Nordisk As	Nye insulinanaloger og anvendelser heraf
CN118754967A (zh) *	2019-12-30	2024-10-11	甘李药业股份有限公司	胰岛素衍生物
CN115385843A (zh) *	2021-05-24	2022-11-25	广东东阳光药业有限公司	一种新型的酰化胰岛素类似物

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3528960A (en)	1968-10-07	1970-09-15	Lilly Co Eli	N-carboxyaroyl insulins
US3869437A (en)	1970-05-08	1975-03-04	Nat Res Dev	Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
GB1381274A (en)	1971-01-28	1975-01-22	Nat Res Dev	Insulin derivatives
US3864325A (en)	1971-11-18	1975-02-04	Nat Res Dev	(N{HU Al{b , N{HU Bl{b , N{HU B29{B , carbamoyl)-(O{HU A14{B , O{HU B16{B , O{HU B26{B aryl) insulin derivatives
JPH01254699A (ja)	1988-04-05	1989-10-11	Kodama Kk	インスリン誘導体及びその用途
HUT56857A (en) *	1988-12-23	1991-10-28	Novo Nordisk As	Human insulin analogues
JP3122128B2 (ja) *	1989-12-21	2001-01-09	ノボノルディスクアクティーゼルスカブ	ペプチド製剤
US6011007A (en)	1993-09-17	2000-01-04	Novo Nordisk A/S	Acylated insulin
US6869930B1 (en)	1993-09-17	2005-03-22	Novo Nordisk A/S	Acylated insulin
EP1132404A3 (en)	1993-09-17	2002-03-27	Novo Nordisk A/S	Acylated insulin
US6703017B1 (en) *	1994-04-28	2004-03-09	Ixion Biotechnology, Inc.	Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US5461031A (en)	1994-06-16	1995-10-24	Eli Lilly And Company	Monomeric insulin analog formulations
US5646242A (en)	1994-11-17	1997-07-08	Eli Lilly And Company	Selective acylation of epsilon-amino groups
US5693609A (en)	1994-11-17	1997-12-02	Eli Lilly And Company	Acylated insulin analogs
US6251856B1 (en)	1995-03-17	2001-06-26	Novo Nordisk A/S	Insulin derivatives
CZ289343B6 (cs)	1995-03-17	2002-01-16	Novo Nordisk A/S	Inzulinový derivát a farmaceutický prostředek pro léčení diabetes
US6451970B1 (en)	1996-02-21	2002-09-17	Novo Nordisk A/S	Peptide derivatives
US5905140A (en)	1996-07-11	1999-05-18	Novo Nordisk A/S, Novo Alle	Selective acylation method
US5898067A (en)	1997-02-07	1999-04-27	Novo Nordisk A/S	Crystallization of proteins
EP1005490B1 (en)	1997-03-20	2006-03-29	Novo Nordisk A/S	Zinc free insulin crystals for use in pulmonary compositions
RU2218349C2 (ru)	1997-10-24	2003-12-10	Ново Нордиск А/С	Агрегаты производных инсулина человека
US6444641B1 (en)	1997-10-24	2002-09-03	Eli Lilly Company	Fatty acid-acylated insulin analogs
JP2001521006A (ja)	1997-10-24	2001-11-06	イーライ・リリー・アンド・カンパニー	不溶性インシュリン組成物
US6451762B1 (en)	1997-10-24	2002-09-17	Novo Nordisk A/S	Aggregates of human insulin derivatives
ZA989744B (en)	1997-10-31	2000-04-26	Lilly Co Eli	Method for administering acylated insulin.
US6531448B1 (en)	1997-12-23	2003-03-11	Eli Lilly And Company	Insoluble compositions for controlling blood glucose
WO1999034821A1 (en)	1998-01-09	1999-07-15	Novo Nordisk A/S	Stabilised insulin compositions
AU8029798A (en)	1998-06-12	2000-01-05	Deutsches Wollforschungsinstitut	Insulin analogue
AU5454200A (en)	1999-06-29	2001-01-31	Eli Lilly And Company	Protamine-free insoluble acylated insulin compositions
AU2001264789A1 (en)	2000-06-08	2001-12-17	Eli Lilly And Company	Protein powder for pulmonary delivery
DE10114178A1 (de)	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
EP1453860A2 (en)	2001-12-02	2004-09-08	Novo Nordisk A/S	Novel glucose-dependant insulins
CZ2004710A3 (cs)	2001-12-20	2005-02-16	Eli Lilly And Company	Inzulínová sloučenina s protrahovaným účinkem
AU2003208316A1 (en)	2002-03-13	2003-09-22	Novo Nordisk A/S	Minimising body weight gain in insulin treatment
US20040138099A1 (en)	2002-11-29	2004-07-15	Draeger Eberhard Kurt	Insulin administration regimens for the treatment of subjects with diabetes
EP1620465A2 (en)	2003-04-29	2006-02-01	Eli Lilly And Company	Insulin analogs having protracted time action
US20060183667A1 (en)	2003-07-11	2006-08-17	Novo Nordisk A/S	Stabilised insulin compositions
WO2005005477A2 (en)	2003-07-11	2005-01-20	Novo Nordisk A/S	Stabilised insulin compositions
CA2531988C (en)	2003-08-05	2016-06-28	Novo Nordisk A/S	Novel insulin derivatives
AU2004264958B2 (en)	2003-08-13	2010-04-15	Biocon, Ltd	Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
EP1687428A1 (en)	2003-11-14	2006-08-09	Novo Nordisk A/S	Processes for making acylated insulin
EP1692168B1 (en)	2003-12-03	2011-07-20	Novo Nordisk A/S	Single-chain insulin
WO2006008238A1 (en)	2004-07-16	2006-01-26	Novo Nordisk A/S	Method for selective acylation
RU2527893C2 (ru)	2004-07-19	2014-09-10	Биокон Лимитед	Инсулин-олигомерные конъюгаты, их препараты и применения
EP2256130B1 (en)	2005-02-02	2013-09-25	Novo Nordisk A/S	Novel insulin derivatives
US20080171695A1 (en)	2005-02-02	2008-07-17	Novo Nordisk A/S	Insulin Derivatives
JP2008533100A (ja)	2005-03-18	2008-08-21	ノボノルディスクアクティーゼルスカブ	Ｐｅｇ化された単鎖インスリン
ES2371361T3 (es)	2005-12-28	2011-12-30	Novo Nordisk A/S	Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
DE602007009496D1 (de)	2006-02-27	2010-11-11	Novo Nordisk As	Insulinderivate
WO2007128815A1 (en)	2006-05-09	2007-11-15	Novo Nordisk A/S	Insulin derivative
EP2015770B1 (en)	2006-05-09	2012-09-26	Novo Nordisk A/S	Insulin derivative
JP2009544716A (ja)	2006-07-27	2009-12-17	ノバルティスアクチエンゲゼルシャフト	肺送達のためのインスリン含有エアロゾル化可能製剤
CN101573133B (zh)	2006-07-31	2014-08-27	诺沃-诺迪斯克有限公司	Peg化延长的胰岛素
RU2524150C2 (ru) *	2006-09-22	2014-07-27	Ново Нордиск А/С	Аналоги инсулина, устойчивые к протеазам
WO2008145721A2 (en)	2007-06-01	2008-12-04	Novo Nordisk A/S	N-terminal modification of polypeptides for protection against degradation by aminopeptidases
JP5552046B2 (ja)	2007-06-13	2014-07-16	ノボ・ノルデイスク・エー／エス	インスリン誘導体を含有する薬学的製剤
WO2009015456A1 (en)	2007-07-30	2009-02-05	Generex Pharmaceuticals Inc.	Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
US9150633B2 (en)	2007-08-15	2015-10-06	Novo Nordisk A/S	Insulin analogues with an acyl and alkylene glycol moiety
EP2217621B1 (en)	2007-11-08	2015-04-22	Novo Nordisk A/S	Insulin derivative
BRPI0820535B8 (pt)	2007-11-16	2021-05-25	Novo Nordisk As	composições farmacêuticas contendo insulina e um peptídeo insulinotrópico
MX2010005317A (es)	2007-11-20	2010-06-02	Ambrx Inc	Polipeptidos de insulina modificados y sus usos.
WO2009112583A2 (en)	2008-03-14	2009-09-17	Novo Nordisk A/S	Protease-stabilized insulin analogues
HUE032284T2 (en) *	2008-03-18	2017-09-28	Novo Nordisk As	Protease-stabilized, acylated insulin analogues
ES2561208T3 (es)	2008-09-12	2016-02-25	Novo Nordisk A/S	Método de acilación de un péptido o una proteína
JP4959005B2 (ja)	2008-10-30	2012-06-20	ノボ・ノルデイスク・エー／エス	毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
AU2009335715B2 (en)	2008-12-19	2016-09-15	Indiana University Research And Technology Corporation	Amide-based insulin prodrugs
EP2448962B1 (en)	2009-06-30	2016-10-19	Novo Nordisk A/S	Insulin derivatives
NZ597964A (en) *	2009-07-31	2014-04-30	Sanofi Aventis Deutschland	Long acting insulin composition
MX2012012943A (es)	2010-05-10	2012-11-29	Novo Nordisk As	Proceso para preparacion de complejos de insulina-cinc.
JP5973427B2 (ja)	2010-06-23	2016-08-23	ノヴォノルディスクアー／エス	追加のジスルフィド結合を含有するインスリン類似体
KR20130036290A (ko) *	2010-06-23	2013-04-11	노보 노르디스크 에이/에스	추가 이황화 결합을 함유하는 인슐린 유도체
CN103415300B (zh)	2010-07-20	2018-02-23	诺沃—诺迪斯克有限公司	N‑末端修饰的fgf21化合物
CN103596584B (zh) *	2011-06-15	2016-12-14	诺沃—诺迪斯克有限公司	多取代的胰岛素
KR20150021011A (ko)	2011-10-27	2015-02-27	케이스 웨스턴 리저브 유니버시티	초고도 농축된, 속효성 인슐린 유사체 제형

2015
- 2015-02-25 AR ARP150100559A patent/AR099569A1/es unknown
- 2015-02-26 PT PT157071028T patent/PT3110840T/pt unknown
- 2015-02-26 PL PL15707102T patent/PL3110840T3/pl unknown
- 2015-02-26 MX MX2016010899A patent/MX368387B/es active IP Right Grant
- 2015-02-26 US US15/121,206 patent/US10040839B2/en active Active
- 2015-02-26 EP EP15707102.8A patent/EP3110840B1/en active Active
- 2015-02-26 JP JP2016554498A patent/JP6580583B2/ja active Active
- 2015-02-26 WO PCT/EP2015/053989 patent/WO2015128403A2/en not_active Ceased
- 2015-02-26 RU RU2016135543A patent/RU2684456C2/ru active
- 2015-02-26 ES ES15707102T patent/ES2831848T3/es active Active
- 2015-02-26 AU AU2015222135A patent/AU2015222135B2/en not_active Ceased
- 2015-02-26 HU HUE15707102A patent/HUE051355T2/hu unknown
- 2015-02-26 DK DK15707102.8T patent/DK3110840T3/da active
- 2015-02-26 RS RS20201399A patent/RS61137B1/sr unknown
- 2015-02-26 CA CA2941103A patent/CA2941103A1/en not_active Withdrawn
- 2015-02-26 TW TW104106145A patent/TWI686403B/zh not_active IP Right Cessation
- 2015-02-26 HR HRP20201732TT patent/HRP20201732T1/hr unknown
- 2015-02-26 BR BR112016017193A patent/BR112016017193A2/pt not_active Application Discontinuation
- 2015-02-26 SI SI201531416T patent/SI3110840T1/sl unknown
- 2015-02-26 CN CN201580010746.3A patent/CN106459171B/zh active Active
- 2015-02-26 KR KR1020167024826A patent/KR20160125988A/ko not_active Withdrawn
2016
- 2016-07-13 IL IL246757A patent/IL246757B/en active IP Right Grant
- 2016-08-21 SA SA516371705A patent/SA516371705B1/ar unknown

Also Published As

Publication number	Publication date
KR20160125988A (ko)	2016-11-01
PT3110840T (pt)	2020-11-26
JP2017508741A (ja)	2017-03-30
CN106459171B (zh)	2020-12-15
WO2015128403A3 (en)	2015-12-10
BR112016017193A2 (pt)	2017-10-03
TWI686403B (zh)	2020-03-01
HRP20201732T1 (hr)	2020-12-25
US10040839B2 (en)	2018-08-07
RU2016135543A (ru)	2018-03-30
AU2015222135B2 (en)	2018-12-20
IL246757B (en)	2020-04-30
HUE051355T2 (hu)	2021-03-01
US20170008945A1 (en)	2017-01-12
EP3110840A2 (en)	2017-01-04
EP3110840B1 (en)	2020-10-21
RS61137B1 (sr)	2020-12-31
CA2941103A1 (en)	2015-09-03
IL246757A0 (en)	2016-08-31
PL3110840T3 (pl)	2021-04-06
MX368387B (es)	2019-10-01
ES2831848T3 (es)	2021-06-09
AR099569A1 (es)	2016-08-03
MX2016010899A (es)	2016-11-18
CN106459171A (zh)	2017-02-22
TW201620930A (zh)	2016-06-16
SA516371705B1 (ar)	2019-10-08
SI3110840T1 (sl)	2020-12-31
AU2015222135A1 (en)	2016-07-28
RU2016135543A3 (da)	2018-08-30
WO2015128403A2 (en)	2015-09-03
JP6580583B2 (ja)	2019-09-25
RU2684456C2 (ru)	2019-04-09

Publication	Publication Date	Title
DK3110840T3 (da)	2020-11-02	A22k, desb27, b29r, des b30, ved epsilon-position af lysin 22 acyleret human insulinanalog
IL258402B1 (en)	2023-03-01	Electroporation for obesity or diabetes treatment
DK3240612T3 (da)	2021-01-18	Fremgangsmåder til behandling af nethindesygdomme
LT2916860T (lt)	2020-07-10	Diabeto gydymui skirta kompozicija, apimanti oksintomodulino analogą
DK3258919T3 (da)	2020-03-23	Næsepulverformulering til behandling af hypoglykæmi
DK3390390T3 (da)	2021-12-06	Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3097085T3 (da)	2020-10-26	Benzoxazinonderivater til behandling af hudsygdomme
DK3554534T3 (da)	2021-08-23	Farmaceutisk sammensætning omfattende insulin
MA40911A (fr)	2017-09-12	Compositions de piégeage d'oxygène ne nécessitant pas de période d'induction
IL248779A0 (en)	2017-01-31	Pharmaceutical compositions for treating infectious diseases
DK3241551T3 (da)	2020-11-09	Farmaceutisk sammensætning til behandling af kræft, indeholdende lactatmetalsalt
DK3302573T3 (da)	2019-11-11	Sammensætning til behandlingen af hjernelæsioner
GB2541840B (en)	2017-09-06	Ophthalmic composition for the treatment of ocular infection
IL258137A (en)	2018-05-31	HIV treatment measures
DK3506956T3 (da)	2021-06-14	Lægemiddel, særlig til behandling af fistler
DK3325027T3 (da)	2024-01-02	Medicinsk implantat
DK3096775T3 (da)	2023-03-27	SOCS-mimetika til behandling af sygdomme
IL251392B (en)	2020-11-30	Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
IL257930A (en)	2018-05-31	A composition for use in the treatment of intervertebral disc-related pain
DK3395350T3 (da)	2022-07-11	Lægemiddel til behandling af hjerneinfarkt
EP3369419C0 (en)	2024-08-28	COMPOSITION FOR THE TREATMENT OF DIABETES
ZA201804588B (en)	2019-09-25	Pharmaceutical formulations for the treatment of diabetes
LT3519050T (lt)	2023-08-25	Kompozicijos, skirtos oftalmologinių būklių gydymui
EP3485888A4 (en)	2020-03-11	DRUG COMPOSITION FOR INHALATION
HUE051834T2 (hu)	2021-03-29	A növényi vírusok biológiai ellenõrzése